Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | SVP, R&D, CMO | April 29, 2026 | May 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date April 29, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 177,914 |
Reported balance
After 2026-04-29 transaction · row 1
1 source rowRow 1 · 2026-04-29 · Grant · Acquired 100,111 · Balance 177,914 F1: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. F2: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
F2: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 29, 2026 Filed May 1, 2026 20:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 100,111 | $0.00 | $0.00 |
DisclosureSEC source: 0002044279-26-000007 · wk-form4_1777667370.xml · nonDerivative · entry 1 Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,914 F1 · deemedExecutionDate: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. F2 · shares: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 02:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 10,636 | $8.44 | $89,767.84 |
DisclosureSEC source: 0002044279-26-000003 · wk-form4_1772763692.xml · nonDerivative · entry 1 Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,803 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 02:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to buy) · Derivative | 44,834 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0002044279-26-000003 · wk-form4_1772763692.xml · derivative · entry 2 Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,833 Underlying: Common Stock · 44,834 shares Expires 2033-03-02 F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| December 14, 2025 Filed Dec 16, 2025 21:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 3,543 | $11.41 | $40,425.63 |
DisclosureSEC source: 0002044279-25-000003 · wk-form4_1765919534.xml · nonDerivative · entry 1 Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,439 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001367644-25-000050 · wk-form4_1741637867.xml · derivative · entry 2 Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,999 Underlying: Common Stock · 62,500 shares Expires 2032-03-05 F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-25-000050 · wk-form4_1741637867.xml · nonDerivative · entry 1 Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,982 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:44 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to buy) · Derivative | 40,499 | $0.00 Strike: $8.48 | $0.00 |
DisclosureSEC source: 0001367644-24-000193 · wk-form4_1734475436.xml · derivative · entry 2 Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,499 Underlying: Common Stock · 40,499 shares Expires 2031-12-14 F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:44 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 29,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-24-000193 · wk-form4_1734475436.xml · nonDerivative · entry 1 Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,482 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.